CRISPR

The Readout LOUD Damian Garde, Allison DeAngelis, and Adam Feuerstein

Humira’s legacy, CEO symbolism, and genomic surgery

In the Lab Megan Molteni

Meet the fetal surgeon forging CRISPR’s next frontier: curing diseases in the womb

Biotech Robert Weisman — Boston Globe

STAT Plus: The Jewish American and Palestinian American scientists who’ve been partnering for 14 years on science’s toughest challenges

The Readout Meghana Keshavan

STAT Plus: Regeneron is interested in obesity treatments that combat muscle loss

Biotech Megan Molteni

STAT Plus: CRISPR-edited pig liver from eGenesis passes first test in brain-dead human, researchers say

The Readout Damian Garde

STAT Plus: The big any-day-now biotech news we’re keeping an eye on

Biotech Adam Feuerstein

STAT Plus: FDA expands approval of CRISPR-based medicine to treat beta thalassemia

The Readout Damian Garde, Adam Feuerstein, Matthew Herper, and Allison DeAngelis

STAT Plus: JPM Day 3 had a cautiously optimistic outlook

The Readout Damian Garde, Adam Feuerstein, Matthew Herper, and Allison DeAngelis

STAT Plus: JPM Day 2 has arrived. Here are the can’t-miss moments of the event so far

Biotech Jason Mast

STAT Plus: Doudna institute hatches plan to ‘cure hundreds of diseases’ left behind by CRISPR revolution

Adam Feuerstein, Allison DeAngelis, Damian Garde, and Matthew Herper

STAT Plus: This is the TLDR of JPM Day 1

The Readout Meghana Keshavan

STAT Plus: Why did Allogene cancel two clinical trials for its off-the-shelf cell therapy?

Exclusive Jason Mast

STAT Plus: Feng Zhang’s year-old CRISPR delivery startup Aera lays off quarter of staff

The Readout Damian Garde

STAT Plus: Why CG Oncology will be the first test of 2024’s IPO waters

Biotech Megan Molteni

STAT Plus: 3 CRISPR advances to watch in 2024

Morning Rounds Elizabeth Cooney

Morning Rounds: Our newsroom’s favorite stories of 2023

Morning Rounds Elizabeth Cooney

Morning Rounds: Why health care costs are nearly a fifth of the GDP

The Readout Damian Garde

STAT Plus: BioMarin appeases an activist

Health Jason Mast

After ‘SNL’ skit on sickle cell CRISPR therapy, advocates cite errors and stereotypes

Biotech Damian Garde

STAT Plus: 3 trends to watch in biotech in 2024

Biotech Andrew Joseph

STAT Plus: European regulators endorse Casgevy, paving way for approval of CRISPR-based therapy

The Readout Damian Garde

STAT Plus: Is it time to worry about Moderna?

Biotech Jason Mast

STAT Plus: After decade-long dispute over CRISPR-Cas9, Editas strikes deal with Vertex to cash in

The Readout Damian Garde

STAT Plus: A plot to solve the ‘whack-a-mole’ of drug discovery

Biotech Jason Mast

STAT Plus: Could sickle cell someday be treated not with CRISPR, but with a pill?

First Opinion Robert Brodsky

New sickle cell disease CRISPR treatments can’t make up for the shortage of adult hematologists

The Readout Theresa Gaffney

Morning Rounds: Preterm birth rates vary across the U.S., with the highest in the Southeast

Biotech Jonathan Wosen

STAT Plus: Historic approval of sickle cell gene therapies met with cautious optimism by experts at ASH

Biotech Adam Feuerstein

STAT Plus: A Q&A with the CEO of CRISPR Therapeutics on a historic approval and the road ahead